Pavel Kapysh / Shutterstock.com
US-based Vertex Pharmaceuticals has announced it will pay $950 million to acquire Semma Therapeutics, a biotechnology company focused on researching a cure for Type 1 diabetes.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Vertex Pharmaceuticals, Semma Therapeutics, biotech, diabetes, mergers and acquisitions, M&A, cell delivery, insulin secretion